MTOR and acute lymphoblastic leukemia: In the clinical context, the GSEA signatures for c-MYC and mTOR pathways were significantly enriched in T-ALL/LBL samples with JAK/STAT pathway mutations and elevated PIM1 expression compared to control thymocytes (Fig. 4g).